Table 2.
Vaccine efficacy against VMCCI, CCI, and LCI in the Per-Protocol analyses.
| Season 1 2005-2006 |
Season 2 2006-2007 |
Overall | Overall efficacy (97.5% CI lower bound) | ||||
|---|---|---|---|---|---|---|---|
| Vaccine N = 1706 n (%) |
Placebo N = 1725 n (%) |
Vaccine N = 2011 n (%) |
Placebo N = 2043 n (%) |
Vaccine N = 3714 n (%) |
Placebo N = 3768 n (%) |
||
| VMCCI | 14 (0.8) | 30 (1.7) | 9 (0.4) | 15 (0.7) | 23 (0.6) | 45 (1.2) | 46.3% (9.8%) |
| CCI | 19 (1.1) | 38 (2.2) | 11 (0.5) | 22 (1.1) | 30 (0.8) | 60 (1.6) | 49.4% (20.3%) |
| LCI | 24 (1.4) | 69 (4.0) | 20 (1.0) | 53 (2.6) | 44 (1.2) | 122 (3.2) | 63.2% (48.2%) |
VMCCI, culture-confirmed influenza A and B matching vaccine; CCI, any culture-confirmed influenza A and B; LCI, any culture- or serology-confirmed influenza A or B; CI, Confidence Interval